|Dr. Arun Swarup Menawat||Chairman & CEO||1.39M||N/A||1955|
|Mr. Aaron Davidson M.B.A., MBA||CFO & Sr. VP of Corp. Devel.||233.22k||N/A||1968|
|Dr. Mathieu Burtnyk||Vice-Pres of Clinical Affairs||166.57k||N/A||N/A|
|Mr. Stephen Kilmer||Investor Relations||N/A||N/A||N/A|
|Mr. Jacques F. Cornet||VP of Marketing & Bus. Devel.||N/A||N/A||1956|
|Mr. Michael Mydra||VP & Head of Global Market Access||N/A||N/A||N/A|
Profound Medical Corp., together with its subsidiaries, operates as a medical technology company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Profound Medical Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.